{
  "study_id": "GXF-203-E",
  "study_name": "GXF-203-E",
  "sponsor": "GeneXpression Therapeutics",
  "title": "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GXF-203 in Patients with Amyotrophic Lateral Sclerosis",
  "phase": "2",
  "indication": "Amyotrophic Lateral Sclerosis",
  "therapeutic_area": "Neurology",
  "indication_level_quotes": "892",
  "therapeutic_area_quotes": "12295",
  "population": {
    "age_range": "18 to 75 years",
    "condition": "Amyotrophic Lateral Sclerosis",
    "inclusion_highlights": [
      "Clinically diagnosed ALS",
      "ALSFRS-R score ≥ 25",
      "Forced vital capacity ≥ 60%",
      "Able to swallow study medication"
    ]
  },
  "design": {
    "randomization": "Yes",
    "control": "Placebo-controlled",
    "blinding": "Double-blind",
    "arms": 2,
    "multicenter": true
  },
  "total_visits": 12,
  "visit_schedule_json": "gxf_203_e_visit_schedule.json"
} 